Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 3;28(10):829-831.
doi: 10.1093/oncolo/oyad248.

Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

Elie Rassy  1   2 , Fabrice Andre  1   3
Affiliations

Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

Elie Rassy et al. Oncologist. .

Abstract

This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framework of this approach is based on the integration of basic biology, biotechnologies, data sciences, clinical research, and social sciences.

PubMed Disclaimer

Conflict of interest statement

Elie Rassy reported honoraria from Eli Lilly; travel, accommodations, expenses from Pfizer, Roche, and Mundipharma; and grants from Gilead (institutional). Fabrice Andre reported research funding from AstraZeneca, Novarti, Pfizer, Eli Lilly, Roche, and Daiichi (institutional); travel, accommodations, expenses from Novartis, Roche, GlaxoSmithKline, and AstraZeneca; ad boards or symposium compensated to the hospital from AstraZeneca, Lilly, Novartis, Pfizer, Daiichi-Sankyo, Relay Tx, and Roche; ad board compensated to the author from Lilly.

Figures

Figure 1.
Figure 1.
Precision oncology in cancer of unknown primary.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. 10.1158/2159-8290.CD-21-1059 - DOI - PubMed
    1. Fidler IJ. Commentary on “tumor heterogeneity and the biology of cancer invasion and metastasis.”. Cancer Res. 2016;76(12):3441-3442. 10.1158/0008-5472.CAN-16-1330 - DOI - PubMed
    1. Garattini S, Nerini IF, D’Incalci M.. Not only tumor but also therapy heterogeneity. Ann Oncol. 2018;29(1):13-18. 10.1093/annonc/mdx646 - DOI - PubMed
    1. Schwartzberg L, Kim ES, Liu D, Schrag D.. Precision oncology: who, how, what, when, and when not?. Am Soc Clin Oncol Educ Book. 2017(37):160-169. 10.1200/edbk_174176 - DOI - PubMed
    1. Mosele F, Remon J, Mateo J, et al. . Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-1505. 10.1016/j.annonc.2020.07.014 - DOI - PubMed